Maravai LifeSciences (NASDAQ:MRVI) Hits New 1-Year Low – Time to Sell?

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) reached a new 52-week low during trading on Wednesday . The stock traded as low as $2.25 and last traded at $2.31, with a volume of 1169004 shares. The stock had previously closed at $2.58.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Bank of America reduced their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, March 3rd. Robert W. Baird downgraded shares of Maravai LifeSciences from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $9.00 to $3.00 in a research note on Wednesday, February 26th. Guggenheim assumed coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. Baird R W downgraded shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group downgraded shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.28.

Maravai LifeSciences Stock Down 1.2 %

The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The firm has a market cap of $606.07 million, a PE ratio of -1.46 and a beta of -0.08. The business’s 50-day simple moving average is $4.01 and its 200 day simple moving average is $5.88.

Insider Activity

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the sale, the general counsel now directly owns 167,618 shares in the company, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

A number of institutional investors have recently modified their holdings of the company. Alpha Wealth Funds LLC bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at about $386,000. Delta Investment Management LLC boosted its stake in Maravai LifeSciences by 285.4% in the 4th quarter. Delta Investment Management LLC now owns 332,993 shares of the company’s stock worth $1,815,000 after purchasing an additional 246,592 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Maravai LifeSciences by 22.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 251,214 shares of the company’s stock worth $1,369,000 after purchasing an additional 45,454 shares in the last quarter. Systematic Financial Management LP boosted its stake in Maravai LifeSciences by 2.3% in the 4th quarter. Systematic Financial Management LP now owns 1,649,544 shares of the company’s stock worth $8,990,000 after purchasing an additional 37,383 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new stake in Maravai LifeSciences in the 4th quarter worth approximately $78,000. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.